|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Center for Research Resources (NCRR) UNC Lineberger Comprehensive Cancer Center |
| Information provided by: | Office of Rare Diseases (ORD) |
| ClinicalTrials.gov Identifier: | NCT00006061 |
Purpose
OBJECTIVES: I. Determine whether plasma choline and breast milk choline levels are low at fasting in a patient with methionine adenosyltransferase deficiency, and if the choline levels are low, determine whether choline levels respond to dietary supplementation with phosphatidylcholine.
II. Determine whether this patient has a fatty liver by magnetic resonance spectroscopy.
| Condition | Intervention |
|
Methionine Adenosyltransferase Deficiency Metabolism, Inborn Errors |
Drug: phosphatidylcholine |
| Genetics Home Reference related topics: | hypermethioninemia |
| Drug Information available for: | Methionine Lecithin |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Estimated Enrollment: | 1 |
| Study Start Date: | January 2000 |
| Estimated Study Completion Date: | January 2000 |
PROTOCOL OUTLINE:
Blood is drawn for liver function tests and measurement of plasma choline levels and breast milk samples are taken for measurement of breast milk choline levels at fasting and at 1 hour after breakfast on day 1. The patient then undergoes magnetic resonance spectroscopy of the liver to assess liver density and choline compound mass. The patient then receives oral phosphatidylcholine supplement, and plasma and breast milk samples are taken at 3 and 6 hours after the dose. Oral phosphatidylcholine supplements continue for 30 days. The above studies are repeated on day 31.
Eligibility
| Ages Eligible for Study: | 20 Years to 20 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Contacts and Locations| National Center for Research Resources (NCRR) |
| UNC Lineberger Comprehensive Cancer Center |
| Study Chair: | Steven H. Zeisel | UNC Lineberger Comprehensive Cancer Center |
More Information
| Study ID Numbers: | 199/15077, UNCCH-GCRC-1405 |
| First Received: | July 5, 2000 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00006061 |
| Health Authority: | United States: Federal Government |
|
|
|